C16orf77 Inhibitors
Chemical inhibitors of C16orf77 can modulate its function through various mechanisms, each distinct based on the signaling pathway the chemical targets. Staurosporine and Bisindolylmaleimide I are examples of such inhibitors, acting on protein kinases which C16orf77 relies on for its activity. Staurosporine is a broad-spectrum protein kinase inhibitor, exerting its effect by directly inhibiting kinase activity that is essential for C16orf77 function. On the other hand, Bisindolylmaleimide I specifically targets protein kinase C (PKC), which is upstream of C16orf77. By inhibiting PKC, Bisindolylmaleimide I indirectly leads to decreased activity of C16orf77.
Further into the cellular signaling network, LY294002 and Wortmannin exert their effects by inhibiting phosphoinositide 3-kinases (PI3K), thus preventing the activation of downstream pathways in which C16orf77 is involved. By blocking PI3K, these inhibitors functionally reduce the activity of C16orf77. Similarly, Rapamycin acts on the mammalian target of rapamycin (mTOR) pathway, a central cellular signaling hub. Inhibition of mTOR by Rapamycin can diminish C16orf77's function if its activity is regulated by or downstream of the mTOR pathway. Complementing these, U0126 and PD98059 focus on the MEK/ERK pathway. As MEK inhibitors, they prevent the activation of ERK, a protein kinase that regulates various cellular functions. If C16orf77 operates within this pathway, its activity would be decreased by these inhibitors. SB203580 and SP600125 add to the array by targeting the p38 MAPK and JNK signaling pathways, respectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. C16orf77 activity can be inhibited by staurosporine through the direct inhibition of kinase activity that C16orf77 requires for its function. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). It inhibits C16orf77 by targeting PKC which is upstream in the signaling pathway that C16orf77 is part of, leading to a decrease in its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it prevents the activation of downstream pathways that C16orf77 is involved in, thereby leading to a functional inhibition of C16orf77. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central component of a cellular signaling pathway. By inhibiting mTOR, Rapamycin can decrease the activity of C16orf77 if C16orf77 functions downstream of or is regulated by the mTOR pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which subsequently inhibits ERK activation. By inhibiting this pathway, U0126 can decrease the functional activity of C16orf77, given that C16orf77 relies on the MEK/ERK pathway for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibiting p38 MAPK can lead to decreased activity of C16orf77 if C16orf77 is involved in the p38 MAPK signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK. By blocking the MEK pathway, it can lead to functional inhibition of C16orf77 if C16orf77's activity is dependent on the MEK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. By inhibiting JNK signaling, SP600125 can functionally inhibit C16orf77 if C16orf77 operates within the JNK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, Wortmannin can functionally reduce the activity of C16orf77, assuming C16orf77 is part of or regulated by the PI3K/Akt pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor. It can functionally inhibit C16orf77 by blocking the signaling pathways mediated by receptor tyrosine kinases that are necessary for C16orf77's activity. | ||||||